|Print Page Close Window|
Stockholder OverviewCorvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Since we began operations in November 2014, we have built a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. ...
NASDAQ CRVS (Common Stock)
$8.17 + 0.69 (9.22%)
02/23/184:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
Corvus Pharmaceuticals Announces Presentation of New Data from Preclinical Study of Novel T-Cell Signaling Pathway Inhibitor at 10th Annual T-Cell Lymphoma Forum02/01/18
Corvus Pharmaceuticals Announces Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient Selection11/11/17
Corvus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Clinical Program Update11/02/17
There are currently no events scheduled.